Effectiveness and Safety of Secukinumab in Chinese Patients with Plaque Psoriasis in a Clinical Practice Setting: a Pilot Study
Zhu Si-Man,Wang Wen-Hui,Guo Jin-Zhu,Guan Xin,Men Yue-Hua,Zhang Hua,Zhao Yi-Ming,Zhang Chun-Lei
DOI: https://doi.org/10.1097/cm9.0000000000001258
IF: 6.133
2020-01-01
Chinese Medical Journal
Abstract:the eligibility criteria for the phase III RCT: ten patients To the Editor: Psoriasis is a chronic, recurrent, systemic, immune-mediated inflammatory disease that mainly affects (10/20) did not meet the inclusion criteria, one patient had the skin, nails, and joints. Plaque psoriasis is the most common type of psoriasis, accounting formore than80%to 90% of all cases. Secukinumab, a human IgG monoclonal antibody that antagonizes interleukin 17A (IL-17A), was approved by the US Food andDrugAdministration in 2015 to treat moderate-to-severe plaque psoriasis. A Chinese multicenter, double-blind, placebo-controlled phase III randomized clinical trial (RCT) demonstrated excellent efficacy and safety. Secukinumab has been available on the Chinese market since May 2019, with a recommended dose of 300mg. It is well-known that RCTs, due to their rigorous, normalized design schemes, cannot fully reflect what happens in clinical practice settings. The concept of the “efficacy-effectiveness gap” was also introduced, which supports the importance of real-world study. Here, we retrospectively summarized all the inpatients with plaque psoriasis who were treated with secukinumab at Peking University Third Hospital from June to December 2019. General information (sex, age, weight, body mass index, etc.) and clinical features (disease duration, family history, comorbidities, laboratory tests, previous treatments, concomitant treatments, etc.) were collected from clinical records. The psoriasis area severity index (PASI), body surface area (BSA), dermatology life quality index (DLQI), psoriasis scalp severity index (PSSI), nail psoriasis severity index (NAPSI), and palmoplantar psoriasis area and severity index (ppPASI) were also recorded. Safety was assessed by adverse events, and special cases that met the exclusion criteria of clinical trials were monitored accordingly. Statistical analysis was performed with SPSS 26.0 software (IBM Corp, Armonk, NY, USA). This study was approved by the Ethical Committee of Peking University Third Hospital (No. 329-01).